<DOC>
	<DOCNO>NCT02584543</DOCNO>
	<brief_summary>This open label , randomize phase VI study , assess safety immunogenicity co-administration Hepatitis E vaccine Hepatitis B vaccine . The concomitant group ( n =300 ) receive Hepatitis B vaccine concomitantly Hepatitis E vaccine day 1 month 1 6 ; The nonconcomitant group ( n =150 ) receive Hepatitis E vaccine day 1 month 1 6 . Another nonconcomitant group ( n=150 ) receive Hepatitis B vaccine day 1 month 1 6 . Anti-HEV IgG HBsAb determine . Injection-site systemic adverse event ( AEs ) monitor 30 day vaccination ; serious AEs monitor throughout study .</brief_summary>
	<brief_title>A Phase Ⅳ Clinical Trial Recombinant Hepatitis E Vaccine ( Escherichia Coli ) ( Coadministration With Recombinant Hepatitis B Vaccine )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy people age 18 year old day enrollment Negative HBsAg , HBsAb HBcAb . Judged healthy eligible vaccination investigator selfreported medical history physical examination . Able understand study information willing comply study requirement . Willing participate study sign inform consent form . Pregnant breastfeed plan get pregnant future 7 month Use investigational product nonregistered product ( drug vaccine ) within 30 day precede first dose study vaccine plan use study period Received immunosuppressed , immunoregulation therapy corticosteroid systemic therapy 14 day 6 month entry , exceptlocal treatment . Administration immunoglobulin blood product within 3 month precede first dose study vaccine , plan use study period . Administration inactivate vaccine within 14 day precede first dose study attenuate live vaccine within 21 day precede first dose study . Had fever ( axillary temperature 38°C ) within 3 day acute illness require systemic antibiotic antiviral treatment within 5 day vaccination . Plan participate clinical trial study period Administration HEV vaccine study . Immunodeficiency ( HIV carrier ) , primary disease important organ , malignant tumor , immune disease ( systemic lupus erythematosus , arthritis pauperum , splenectomy functional asplenia disease might affect immune response ) . History allergic disease history serious adverse event occur vaccination , i.e. , allergy , urticaria , dyspnea , angioneurotic edema abdominal pain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>